EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pharmacogenomics polygenic risk score: Ready or not for prime time?

Sonal Singh iD, Gabriele Stocco iD, Katherine N Theken iD, Alyson Dickson iD, QiPing Feng iD, Jason H Karnes iD, Jonathan D Mosley iD, Nihal El Rouby iD

Clinical and Translational Science · 2024-08 · 17 (8)

DOI: 10.1111/cts.13893 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 30.07.2024. Verfasst von Sonal Singh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Pharmacogenetics, Multifactorial Inheritance, Genome-Wide Association Study, Precision Medicine. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenomic Polygenic Risk Scores (PRS) have emerged as a tool to address the polygenic nature of pharmacogenetic phenotypes, increasing the potential to predict drug response. Most pharmacogenomic PRS have been extrapolated from disease‐associated variants identified by genome wide association studies (GWAS), although some have begun to utilize genetic variants from pharmacogenomic GWAS. As pharmacogenomic PRS hold the promise of enabling precision medicine, including stratified treatment approaches, it is important to assess the opportunities and challenges presented by the current data. This assessment will help determine how pharmacogenomic PRS can be advanced and transitioned into clinical use. In this review, we present a summary of recent evidence, evaluate the current status, and identify several challenges that have impeded the progress of pharmacogenomic PRS. These challenges include the reliance on extrapolations from disease genetics and limitations inherent to pharmacogenomics research such as low sample sizes, phenotyping inconsistencies, among others. We finally propose recommendations to overcome the challenges and facilitate the clinical implementation. These recommendations include standardizing methodologies for phenotyping, enhancing collaborative efforts, developing new statistical methods to capitalize on drug‐specific genetic associations for PRS construction. Additional recommendations include enhancing the infrastructure that can integrate genomic data with clinical predictors, along with implementing user‐friendly clinical decision tools, and patient education. Ethical and regulatory considerations should address issues related to patient privacy, informed consent and safe use of PRS. Despite these challenges, ongoing research and large‐scale collaboration is likely to advance the field and realize the potential of pharmacogenomic PRS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacogeneticsMultifactorial InheritanceGenome-Wide Association StudyPrecision MedicineHumansPhenotypeRisk AssessmentPharmacogenomic VariantsGenetic Risk Score

Autor:innen und Institutionen

  • Merck & Co., Inc, South San Francisco, California, USA.
  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  • Department of Oral and Maxillofacial Surgery and Pharmacology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Pharmacy Practice and Science, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, USA.

ORCID-Profile: Sonal Singh, Gabriele Stocco, Katherine N Theken, Alyson Dickson, QiPing Feng, Jason H Karnes, Jonathan D Mosley, Nihal El Rouby

Förderung

  • NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Singh, S., Stocco, G., Theken, K. N., Dickson, A., Feng, Q., Karnes, J. H., Mosley, J. D., & El Rouby, N. (2024). Pharmacogenomics polygenic risk score: Ready or not for prime time?. Clinical and Translational Science, 17(8). https://doi.org/10.1111/cts.13893

Vancouver

Singh S, Stocco G, Theken KN, Dickson A, Feng Q, Karnes JH, et al. Pharmacogenomics polygenic risk score: Ready or not for prime time?. Clinical and Translational Science. 2024;17(8). doi:10.1111/cts.13893

BibTeX
@article{Singh2024,
  author = {Singh, Sonal and Stocco, Gabriele and Theken, Katherine N and Dickson, Alyson and Feng, QiPing and Karnes, Jason H and Mosley, Jonathan D and El Rouby, Nihal},
  title = {Pharmacogenomics polygenic risk score: Ready or not for prime time?},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1111/cts.13893}
}
Kostenlos starten →